Laporan Laba Rugi (TTM)
Laporan Laba Rugi Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2021 12-31 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32 | 804 | 1,155 | 1,505 | 1,523 | 1,540 | 1,709 | 1,877 | 1,905 | 1,933 | 1,717 | 1,501 |
| Change (%) | 2,387.26 | 43.61 | 30.37 | 1.17 | 1.16 | 10.92 | 9.85 | 1.49 | 1.47 | -11.18 | -12.59 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 23 | 277 | 388 | 500 | 641 | 781 | 733 | 714 | 701 | 659 | 652 | 644 |
| Change (%) | 1,101.19 | 40.16 | 28.65 | 28.18 | 21.98 | -6.23 | -2.59 | -1.72 | -5.98 | -1.19 | -1.20 | |
| % of Revenue | 71.38 | 34.47 | 33.64 | 33.20 | 42.06 | 50.72 | 42.88 | 38.02 | 36.82 | 34.11 | 37.95 | 42.90 |
| Gross Operating Profit | 9 | 527 | 766 | 1,005 | 882 | 759 | 976 | 1,163 | 1,204 | 1,274 | 1,065 | 857 |
| Change (%) | 5,595.08 | 45.43 | 31.24 | -12.25 | -13.96 | 28.58 | 19.19 | 3.46 | 5.81 | -16.36 | -19.56 | |
| % of Revenue | 28.62 | 65.53 | 66.36 | 66.80 | 57.94 | 49.28 | 57.12 | 61.98 | 63.18 | 65.89 | 62.05 | 57.10 |
| SG&A | 91 | 93 | 117 | 140 | 171 | 201 | 208 | 217 | 283 | 346 | 419 | 492 |
| Change (%) | 2.25 | 25.26 | 20.16 | 21.92 | 17.98 | 3.28 | 4.34 | 30.27 | 22.38 | 21.06 | 17.40 | |
| % of Revenue | 281.48 | 11.57 | 10.09 | 9.30 | 11.21 | 13.07 | 12.17 | 11.56 | 14.84 | 17.90 | 24.40 | 32.77 |
| R&D | 728 | 846 | 919 | 993 | 1,012 | 1,031 | 1,112 | 1,193 | 1,200 | 1,206 | 1,186 | 1,165 |
| Change (%) | 16.26 | 8.66 | 7.97 | 1.94 | 1.90 | 7.86 | 7.28 | 0.55 | 0.55 | -1.69 | -1.72 | |
| % of Revenue | 2,251.31 | 105.23 | 79.62 | 65.94 | 66.44 | 66.92 | 65.07 | 63.55 | 62.97 | 62.40 | 69.06 | 77.65 |
| OpEx | 828 | 1,198 | 1,421 | 1,644 | 1,819 | 1,994 | 2,027 | 2,061 | 2,103 | 2,145 | 2,221 | 2,297 |
| Change (%) | 44.75 | 18.61 | 15.69 | 10.66 | 9.64 | 1.67 | 1.64 | 2.05 | 2.01 | 3.54 | 3.42 | |
| % of Revenue | 2,560.37 | 149.00 | 123.06 | 109.20 | 119.44 | 129.45 | 118.65 | 109.78 | 110.39 | 110.97 | 129.37 | 153.07 |
| Operating Income | -795 | -394 | -266 | -138 | -296 | -454 | -319 | -184 | -198 | -212 | -504 | -796 |
| Change (%) | -50.46 | -32.42 | -47.98 | 113.80 | 53.23 | -29.76 | -42.37 | 7.75 | 7.19 | 137.73 | 57.94 | |
| % of Revenue | -2,460.37 | -49.00 | -23.06 | -9.20 | -19.44 | -29.45 | -18.65 | -9.78 | -10.39 | -10.97 | -29.37 | -53.07 |
| Interest Expense | -113 | -149 | -152 | -155 | -120 | -84 | -46 | -8 | -6 | -4 | -4 | -4 |
| Change (%) | 32.17 | 2.10 | 2.06 | -22.82 | -29.56 | -45.21 | -82.50 | -26.52 | -36.09 | 6.78 | 6.35 | |
| % of Revenue | -348.34 | -18.51 | -13.16 | -10.30 | -7.86 | -5.47 | -2.70 | -0.43 | -0.31 | -0.20 | -0.24 | -0.29 |
| Net Income | -890 | -616 | -496 | -376 | -475 | -574 | -403 | -233 | -250 | -267 | -494 | -722 |
| Change (%) | -30.76 | -19.46 | -24.16 | 26.27 | 20.81 | -29.73 | -42.30 | 7.30 | 6.80 | 85.36 | 46.05 | |
| % of Revenue | -2,752.91 | -76.64 | -42.98 | -25.00 | -31.21 | -37.27 | -23.61 | -12.40 | -13.11 | -13.80 | -28.80 | -48.12 |
Source: Capital IQ
